Dr. McDermott on the Role of VEGF Targeted Therapy in RCC

David F. McDermott, MD
Published: Thursday, May 11, 2017



David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma (RCC).

For most newly diagnosed patients, the standard of care is a VEGF-targeted agent, as clear cell kidney cancers are very VEGF driven, McDermott says.

Many patients end up developing resistance though—at least half within the first year—suggesting the need for the development of new therapies in this setting.
 


David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma (RCC).

For most newly diagnosed patients, the standard of care is a VEGF-targeted agent, as clear cell kidney cancers are very VEGF driven, McDermott says.

Many patients end up developing resistance though—at least half within the first year—suggesting the need for the development of new therapies in this setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x